DGX Stock Recent News

Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DGX's first-quarter 2025 performance is likely to have been supported by the ongoing utilization of its Advanced Diagnostics and benefits from acquisitions.

Quest Diagnostics introduces AD-Detect Abeta, a new laboratory blood test, to detect Alzheimer's disease without any PET imaging and cerebral spinal fluid testing.

In an oral presentation at the 2025 AAN Annual Meeting, Quest scientists presented data suggesting the test can accurately assess Alzheimer's disease pathology with greater than 90% sensitivity and specificity SECAUCUS, N.J. , April 9, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced the launch of a new laboratory blood test designed to help physicians confirm amyloid brain pathology due to Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or dementia.

This weekend's stocks to watch are defensive plays. They boast strong relative strength, but still suffered losses amid the market sell-off.

8 Upcoming Dividend Increases During Volatile Times

Providers in the United States may now order the FDA-cleared HPV self-collection solution for their patients to use in their offices or other healthcare settings, with goal to reduce barriers to screening by enabling discreet self-collection Quest also plans to make self-collection option available at its 2,000 patient service centers in the United States early next month, expanding access to screening New solution follows company's launch of GTI self-collection option for several STIs and related conditions last fall SECAUCUS, N.J. , April 2, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a new solution aimed at broadening access to human papillomavirus (HPV) screening to help identify women who are at risk of developing cervical cancer.

SECAUCUS, N.J. , April 1, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2025 financial results on Tuesday, April 22, 2025, before the market opens.

Strong momentum in Advanced Diagnostics and strategic acquisitions continues to attract investors to DGX.

Quest Diagnostics teams up with Google Cloud to streamline data and personalize customer experiences using gen AI.